The Silent Erosion of Scientific Oversight: What Happens When NIH Advisory Boards Empty? For decades, the National Institutes of Health (NIH) has relied on a network of advisory councils – comprised of leading scientists, ethicists, and patient advocates – to guide its research funding decisions. But a concerning trend has emerged: these crucial panels are … Read more
AI Therapy’s Retreat: What Slingshot AI’s UK Exit Signals for the Future of Digital Mental Health The recent decision by Slingshot AI to pull its therapy chatbot, Ash, from the United Kingdom due to regulatory uncertainty isn’t an isolated incident. It’s a stark warning shot across the bow of the rapidly expanding digital mental health … Read more
Healthcare’s Shifting Landscape: What the New Congressional Deal Signals for the Future Washington just witnessed a rare bipartisan agreement on key healthcare policies. While the immediate impact centers on curbing drug costs, increasing hospital billing transparency, boosting pediatric cancer research, and expanding Medicare coverage for multi-cancer screenings, the deal’s implications ripple far beyond these specific … Read more
The Reluctant CMO: Why Top Medical Minds Are Now Weighing In on AI’s Role in Healthcare The story of Dr. Jesse Ehrenfeld, initially declining a Chief Medical Officer position at AI-driven medical imaging firm Aidoc, speaks volumes about a pivotal moment in healthcare. It’s no longer a question of *if* artificial intelligence will transform medicine, … Read more
The Revolving Door in Biotech: Why Executive Moves Signal Future Trends The pharmaceutical and biotechnology industries are known for a high degree of executive mobility. A seemingly simple “coming and going” announcement, like the recent hiring of Roger Waltzman as Chief Medical Officer at Biolojic Design (previously at Indaptus Therapeutics), is actually a powerful indicator … Read more
Supreme Court to Weigh ‘Skinny Labeling’ – What It Means for Generic Drugs and Your Wallet The Supreme Court’s decision to review the practice of “skinny labeling” by generic drug manufacturers is sending ripples through the pharmaceutical industry. This case isn’t just about legal technicalities; it has the potential to significantly impact the availability and … Read more
NIH Funding Face-Off: What the Grant Debate Means for the Future of Medical Research For biomedical researchers in the United States, the flow of funding from the National Institutes of Health (NIH) is the lifeblood of discovery. Last year, anxieties spiked as initial grant awards lagged, raising fears of stalled projects and a slowdown in … Read more
The Looming Shadow Over Dietary Guidelines: What’s Next for Food Policy? The recent revelation that the Biden administration’s expedited dietary guidelines were shaped by researchers with significant financial ties to the food industry has ignited a firestorm of controversy. While the initial promise was a refresh free from corporate influence, the reality appears strikingly different. … Read more
Weight Loss Drugs: The Battle for Access Heats Up – What’s Next? The recent lawsuit filed by Strive Specialties against Eli Lilly and Novo Nordisk isn’t just about one compounding pharmacy; it’s a sign of a much larger battle brewing over the future of weight loss drug access. As demand for medications like Wegovy and … Read more
The Future of CAR-T Therapy: Beyond Multiple Myeloma and Gilead’s Next Moves The recent news regarding Gilead’s submission of anito-cel, a CAR-T therapy for multiple myeloma developed in partnership with Arcellx, isn’t just a single data point. It’s a flashing signal illuminating the evolving landscape of CAR-T (Chimeric Antigen Receptor T-cell) therapy and the broader … Read more